SPECIFIC FEATURES OF THERAPY FOR ERECTILE DYSFNCTI0N IN PATIENTS WITH HYPOGONADISM


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Since erectile dysfunction is frequently accompanied by hypogonadism, this study has been undertaken to define indications for combined therapy with phosphodiesterase type V inhibitors in combination with androgens. Androgen monotherapy have turned out to be effective in 67.6% of patients. It is advisable to use combined therapy to patients with severe and moderate erectile dysfunction, diabetes mellitus and/or coronary heart disease shortly after these conditions are diagnosed. However, there is an earlier occurrence of benefits from therapy with phosphodiesterase type V inhibitors if androgens have been previously used.

About the authors

R Rozhivanov

D Kurbatov

Ft Rozhivanov

Endocrinology Research Center, Russian Agency for Medical Technologies

; Endocrinology Research Center, Russian Agency for Medical Technologies

D Kurbatov

Endocrinology Research Center, Russian Agency for Medical Technologies

; Endocrinology Research Center, Russian Agency for Medical Technologies

References

  1. Курбатов Д. Г., Кузнецкий Ю. Я., Петричко М. И. Лечение эректильной дисфункции у больных с гипогонадизмом // Андрология и генитальная хирургия.-2006; 4:41-47.
  2. Мериних Д., МакДермотт М. Секреты эндокринологии. - М, 1998. - С. 308.
  3. Нарушения половой функции у мужчин при сахарном диабете. Под ред. Коган М.И.-М., 2005. -224 с.
  4. Рафальский В.В. Подходы к рациональному выбору ингибиторов фосфодиэстеразы 5 типа//Фарматека. - 2004; 19(20): 1-8.
  5. Aversa A., Isidori A., De Martino M. et al. Androgens and penile erection: evidence for direct relationship between free testosterone and cavernous vasodilatation in men with erectile dysfunction // Clin Endocrinol. - 2000; 53:517-522.
  6. Brock G. Oral agents: First-line therapy for erectile dysfunction // Eur. Urol. -2002;1:12-18.
  7. Carani C., Granata A., Bancroft J. et al. The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men // Psychoneuroendocrinology. -1995; 20 (7): 743-753.
  8. Carani C., Granata A., Faustini F. et al. Prolactin and testosterone: their role in male sexual function // Int. J. Androl. -1996; 19:48-54.
  9. Feldman H., Golstein I., Hatzichristou D. et al. Importence and its medical and psychological correlates: results of the Massachusetts Male Aging Study // J. Urol. (Baltimore).-1994; 151:54-61.
  10. Finley M., Curruthers M. Androgens, the prostate and safety of testosterone treatment // The Aging Male. - 2006; 9 (1): 4.
  11. Holmquist F., Persson K., Bodker A. et al. Some pre- and postjunctional effects of castration in rabbit isolated corpus cavernosum and urethra // J. Urol. (Baltimore). -1994; 152:1011-1016.
  12. ISA, ISSAM, EAU, E AA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. - The Aging Male. - 2008.
  13. Kurbatov D. Verbesserte Differenzialdiagnose vaskulogener Erektionsstorungen mit Hilfe der Magnitresonanztomographie // Androgen.info. - Nov. 2006. - P. 106-108.
  14. Laumann E., Paik A., Rosen R. Sexual dysfunction in Unuted States: prevalence and predictors //JAMA. -1999; 281:537-544.
  15. National Institutes of health consensus development panel on impotence // JAMA.-1993; 270: 83-90.
  16. Palese M., Crone J., Burnett A. A castrated mouse model of erectile dysfunction // J. Androl. - 2003; 24:699-703.
  17. Park K., Ku J., Kim S. et al. Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction // BJU Int. - 2005; 95 (3): 366-370.
  18. Rochira V., Balestrieri A., Madeo B. et al. Sildenafil Improves Sleep-Related Erections in Hypogonadal Men: Evidence From a Randomized, Placebo-Controlled, Crossover Study of a Synergic Role for Both Testosterone and Sildenafil on Penile Erections // J. Androl. - 2006; 27:165-175.
  19. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function // World J. Urol. -1997; 15 (1): 21-26.
  20. Vernet D., Cai L, Garbin H. et al. Reduction of penile nitrogen oxide synthase in diabetic BB/WOR (type 1) and BBZ/WOZ (type II) rats with erectile dysfunction // Endocrinology. -1995; 136:5709-5717.
  21. Vinik A., Richardson D. Erectile dysfunction in diabetes // Diabetes Rev. -1998; 6(1): 16-33.
  22. Yassin A., Diede H.-E., Saad F. et al. Combination therapy of Tadalafil&Testosterone in hypogonadal non-responders // Int. J. Impot. Res. - 2003; 15 (6): 27.
  23. Yassin A., Saad F. Long-Acting Testosterone Ester injection as a First Line Therapy in hypogonadal patients with Erectile Dysfunction // Int. J. Androl. - 2005; 28 (1):53.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies